BioMarin Pharmaceutical Inc.

77.77+0.6600+0.86%Vol 863.37K1Y Perf -6.29%
Apr 13th, 2021 16:00 DELAYED
BID77.75 ASK79.50
Open77.44 Previous Close77.11
Pre-Market- After-Market77.77
 - -  - -%
Target Price
106.25 
Analyst Rating
Strong Buy 1.38
Potential %
36.62 
Finscreener Ranking
★★★★★     62.24
Insiders Trans % 3/6/12 mo.
-100/-100/-79 
Value Ranking
★★★★+     59.56
Insiders Value % 3/6/12 mo.
-100/-100/-91 
Growth Ranking
★★★★★     82.49
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-88 
Income Ranking
 —    -
Market Cap14.14B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
10.59 
Earnings Date
5th May 2021

Today's Price Range

76.5078.29

52W Range

71.35131.95

5 Year PE Ratio Range

-487.50-13.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.36%
1 Month
1.30%
3 Months
-4.41%
6 Months
-1.29%
1 Year
-6.29%
3 Years
-6.96%
5 Years
-12.47%
10 Years
194.92%

TickerPriceChg.Chg.%
BMRN77.770.66000.86
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
3.10
4.80
0.21
0.26
-0.40
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
71.60
-0.70
5.00
-20.20
58.96
RevenueValueIndustryS&P 500US Markets
1.36B
7.47
10.76
15.00
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.06-0.0516.67
Q03 2020-0.010.293.00K
Q02 2020-0.100.07170.00
Q01 20200.120.38216.67
Q04 20190.010.09800.00
Q03 20190.120.2283.33
Q02 2019-0.05-0.08-60.00
Q01 2019-0.12-0.1016.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.06-66.67Negative
6/2021 QR0.04-50.00Negative
12/2021 FY0.15-72.22Negative
12/2022 FY1.54-22.61Negative
Next Report Date5th May 2021
Estimated EPS Next Report0.06
Estimates Count6
EPS Growth Next 5 Years %31.70
Volume Overview
Volume863.37K
Shares Outstanding181.83M
Trades Count10.68K
Dollar Volume116.61M
Avg. Volume1.31M
Avg. Weekly Volume827.10K
Avg. Monthly Volume1.07M
Avg. Quarterly Volume1.20M

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 77.77 per share at the end of the most recent trading day (a 0.86% change compared to the prior day closing price) with a volume of 863.49K shares and market capitalization of 14.14B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.

The one-year performance of BioMarin Pharmaceutical Inc. stock is -6.29%, while year-to-date (YTD) performance is -11.31%. BMRN stock has a five-year performance of -12.47%. Its 52-week range is between 71.35 and 131.95, which gives BMRN stock a 52-week price range ratio of 10.59%

BioMarin Pharmaceutical Inc. currently has a PE ratio of 17.70, a price-to-book (PB) ratio of 3.46, a price-to-sale (PS) ratio of 10.32, a price to cashflow ratio of 175.70, a PEG ratio of 2.32, a ROA of 15.69%, a ROC of 18.21% and a ROE of 22.89%. The company’s profit margin is 58.96%, its EBITDA margin is 5.00%, and its revenue ttm is $1.36 Billion , which makes it $7.47 revenue per share.

Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.06 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.38), with a target price of $106.25, which is +36.62% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioMarin Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.79, ATR14 : 2.92, CCI20 : 29.49, Chaikin Money Flow : -0.03, MACD : -1.94, Money Flow Index : 46.67, ROC : 4.03, RSI : 45.43, STOCH (14,3) : 70.62, STOCH RSI : 1.00, UO : 43.50, Williams %R : -29.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: David E.I. Pyott (Buy at a value of $2 003 430), Elaine J. Heron (Sold 0 shares of value $-794 700 ), G. Eric Davis (Sold 12 504 shares of value $1 117 607 ), Henry J. Fuchs (Sold 0 shares of value $-9 855 750 ), Henry J. Fuchs (Sold 186 613 shares of value $22 888 787 ), Jean-Jacques Bienaime (Sold 0 shares of value $-3 100 080 ), Jean-Jacques Bienaime (Sold 133 000 shares of value $11 836 194 ), Jeffrey R. Ajer (Sold 0 shares of value $-946 500 ), Jeffrey R. Ajer (Sold 21 262 shares of value $2 345 163 ), Michael G. Grey (Sold 0 shares of value $-264 900 ), Michael G. Grey (Sold 10 000 shares of value $983 150 ), V. Bryan Lawlis (Sold 0 shares of value $-198 675 ), V. Bryan Lawlis (Sold 16 360 shares of value $1 607 671 ), Willard H. Dere (Sold 8 860 shares of value $1 095 185 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (75.00 %)
15 (75.00 %)
15 (75.00 %)
Moderate Buy
2 (10.00 %)
2 (10.00 %)
2 (10.00 %)
Hold
3 (15.00 %)
3 (15.00 %)
3 (15.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Strong Buy
1.38

BioMarin Pharmaceutical Inc.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

CEO: Jean-Jacques Bienaime

Telephone: +1 415 506-6700

Address: 770 Lindaro Street, San Rafael 94901, CA, US

Number of employees: 3 059

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

Bearish Bullish

65%35%

News

Stocktwits